[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551614":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":32,"responsibleParty":47,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":18,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":18,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Proton therapy","EXPERIMENTAL",[12],"Radiation: Proton therapy",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"RADIATION","External beam proton therapy combined with standard cisplatin and brachytherapy",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Hanne Matthiesen, MD, PhD","Department of Oncology, Capital Region Denmark","PRINCIPAL_INVESTIGATOR",[25,29],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},"CONTACT","004592432356","hanne.from.mathiesen@regionh.dk",{"name":30,"role":26,"phone":27,"phoneExt":18,"email":31},"Camilla Kronborg, MD, PhD","camkro@rm.dk",[33],{"facility":22,"status":34,"city":35,"state":18,"zip":18,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Copenhagen","Denmark","DK",{"type":39,"coordinates":40},"Point",[41,42],12.56553,55.67594,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":18,"phoneExt":18,"email":18},"Hanne Matthiesen",{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[50],{"name":51,"class":6},"Aarhus University Hospital","100551614","phase-2-proton-therapy-for-locally-advanced-cervical-cancer-100551614",false,"NCT06462378","Proton Therapy for Locally Advanced Cervical Cancer","Proton Therapy in Locally Advanced Cervical Cancer in Combination With Concomitant Chemotherapy and Brachytherapy","Inclusion Criteria:\n\n* Inclusion criteria:\n\n  * Cancer of the uterine cervix considered suitable for curative treatment with definitive radio- (chemo) therapy including IGABT\n  * Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix.\n  * Staging according to Intenational federation of Gynecology and Obstetrics (FIGO) and TNM guidelines\n  * T1-3N1M0 (FIGO stage IIIC1 (with ≥3 pelvic lymph node metastases) and IIIC2)\n  * Para-aortic metastatic nodes below L1-L2 are allowed (FIGO stage IVB)\n  * Magnetic Resonance Imaging (MRI) and Positron Emission Tomogaraphy-computerized Tomograpy (PET-CT) of the retroperitoneal space and abdomen at diagnosis\n  * Patient written, informed consent\n  * Age≥18 years\n  * Patients must be able to understand a Danish or Swedish\n\nExclusion Criteria:\n\n* Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin\n* Metastatic disease beyond para-aortic region (L1-L2 interspace)\n* Previous pelvic or abdominal radiotherapy\n* Combination of preoperative radiotherapy with surgery\n* Patients receiving neoadjuvant chemotherapy\n* Contra indications to MRI\n* Contra indications to IGABT\n* Contra indications to protontherapy\n* Small cell histology (neuroendocrine tumors)\n* Active infection or severe medical condition endangering treatment delivery\n* Pregnant, lactating or childbearing potential without adequate contraception\n* Human Immune Deficiency Virus (HIV)\n* Patients with no possibility of follow up","FEMALE","18 Years","99 Years",{"count":63,"type":64},55,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The purpose of this protocol is to determine toxicity and efficacy of proton therapy in combination with standard concomitant platinum-based chemotherapy and standard image-guided adaptive brachytherapy (IGABT) in patients with locally advanced cervical cancer (LACC). The over-all aim is to maintain a high disease control and at the same time reduce acute morbidity as well as late side effects after treatment.",[70,71,72],"Cervical Cancer","Proton Therapy","Radiotherapy Side Effect","2024-06-11",{"date":75,"type":76},"2024-06-17","ACTUAL",{"date":78,"type":76},"2024-05-20",{"date":80,"type":64},"2034-05-20",{"name":5,"class":6},1]